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Background 
Faecal microbiota transplant (FMT) is the infusion of donor faeces into the gut aiming to 
improve microbial diversity. The procedure has gained significant interest recently in the 
treatment of recurrent Clostridium difficile infection (CDI). The literature is currently 
dominated by small case series and isolated case reports. There is no standardisation of 
methods and recording of outcomes. 
 
Aim 
The aim of this review is to present the adverse events that have been associated with the use 
of FMT as reported in the English literature to date. 
 
Methods 
A database search of Medline and Embase identified publications where FMT has been 
administered. Review articles were excluded. 109 publications were identified that describing 
the use of FMT in 1555 individuals.  
 
Findings 
Other than three small randomised controlled studies, the data consisted of small series and 
case reports. CDI was the most common indication for FMT (n=1190) with the majority of 
the remaining cases receiving FMT for inflammatory bowel disease. Its use had also been 
applied to irritable bowel syndrome, metabolic syndrome and constipation in small numbers. 
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Adverse events appear to be uncommon, often mild and self-limiting; however serious 
adverse events including bacteraemia, perforations and death have been reported.  
 
Conclusion 
We find the vast majority of adverse events to be mild, self-limiting and gastrointestinal in 
nature. In some a credible association is not established, due to the lack of controlled data. 
There is a need for standardised, randomised controlled trials both to qualify and quantify the 
risks associated with FMT. 
 
Keywords: Faecal microbiota transplant, complications, adverse events, Clostridium difficile 
infection, inflammatory bowel disease.  
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Adverse events in Faecal Microbiota Transplant (FMT) a review of the 
literature 
 
Background 
The recurrence rate of a conventionally treated first episode of Clostridium difficile infection 
(CDI), with vancomycin or metronidazole is up to 30%. (1,2) Should relapse occur the risk of 
further recurrence then rises to 40-50%. (3) In addition CDI has increased in both incidence 
and severity globally. (4,5) 
 
The suboptimal nature of CDI management has driven the search for alternative therapies. 
This includes the licensing of the macrolide fidaxomicin, found in phase 3 clinical trials to be 
non-inferior to vancomycin for acute diarrhea but with a 45% relative reduction in  
recurrence rates, possibly due to less disruption of the intestinal microbiome.(5) Faecal 
microbiota transplant (FMT) that is, the infusion of donor stool into the gut with the aim of 
improving microbial diversity, has also been the subject of significant interest in recent years. 
FMT has successfully been used in the treatment of recurrent Clostridium difficile infection 
(CDI). (1,2) 
 
Faecal microbiota transplant was first described in 1958 as a treatment of “Staphylococcal 
pseudomembranous enterocolitis”. (6) In the last 5 years there has been an explosion of 
interest (Figure 1), and it has become an accepted treatment option for CDI. There is also 
interest in the application of FMT in a variety of other conditions including inflammatory 
bowel disease. (7)  
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The literature is currently dominated by small case series and isolated case reports. There is 
no standardisation of methods and recording of outcomes. There has only been one 
randomised control trial of FMT in the treatment of CDI to date (8) finding FMT superior to 
vancomycin in efficacy. The emergent body of published evidence finds FMT efficacious 
with low rates of adverse events (4,7)  but these are as yet to be adequately quantified. The aim 
of this review is to present the adverse events as reported in the English literature to date.  
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Materials and Methods 
 
Medline and Embase were individually searched using the terms f(a)ecal transplant, f(a)ecal 
transplantation,  f(a)eces transplant,  f(a)eces transplantation, f(a)ecal bacteriotherapy, 
f(a)ecal microbiota transplant, f(a)ecal microbiota transplantation, f(a)ecal microbiota 
transplanted, f(a)ecal bacteria therapy, stool infusion, stool infused, f(a)eces infused, f(a)eces 
infusion, f(a)ecal infusion,  f(a)ecal infused, f(a)eces within 2 words of infusion or infused, 
f(a)eces enema, f(a)ecal enema (Figure 2). This yielded 5579 citations for which the abstracts 
and keywords were searched for terms pertaining to faecal transplant. After duplicates were 
removed 383 publications relevant to faecal microbiota FMT were identified. Papers and 
abstracts that described first-hand experience of the use of faecal transplant were identified 
for inclusion, and review and discussion articles were excluded. After further removal of 
papers which essentially described previously published cohorts of cases, 109 publications 
were identified that described the use and outcomes of FMT. Three further publications were 
identified from trawling bibliographies. All published papers were obtained in full. 
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Results 
The 109 publications described the use of FMT in 1555 patients. This included individual 
cases, uncontrolled series and three randomised controlled trials. For 1190 individuals the 
indication was given as Clostridium difficile infection (Table I).  
 
Randomised Control Trials 
There have been three published RCTs using FMT to date. (8–10) A double blinded RCT 
assessing FMT as an intervention for metabolic syndrome (9) randomised patients to duodenal 
infusion of autologous faeces (n=9) or donor faeces (n=9) and observed no adverse events in 
either arm. A trial in Ulcerative Colitis (UC) randomised patients to receive donor faeces 
(n=27) or placebo (water) (n=26) as 50ml retention enemas once weekly for 6 weeks (10) and 
also reported no adverse events.  The only RCT to date assessing FMT specifically for CDI(8) 
involved randomising participants to one of three therapies 1) vancomycin followed by bowel 
lavage and subsequent infusion of donor faeces via nasoduodenal tube (n=16). 2) 
Vancomycin treatment for 14 days with bowel lavage on day 4-5 (n=13) or 3) Vancomycin 
for 14 days alone (n=13). The adverse events from this study are listed in Table II. 
 
Non-controlled studies 
FMT to treat Clostridium difficile (n=1174) 
The reports on 1174 patients describe FMT primarily for CDI without controls.  Publications 
comprised 30 single case reports (11–40) and case series (1,3,41–83) ranging from 2 cases 
(41,43,44,46,48) to the largest series of 146 cases. (68) In 32 cases undergoing FMT primarily for 
CDI inflammatory bowel disease was also present. (15,21,25,29,32,36,38,44,45,56,63,80) 
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Modes of delivery 
Methods of administration were specified in 946 cases, comprising nasogastric tube (n=133); 
(1,15,21,23,37,42,49,65,79,80) naso-jejunal / nasoduodenal tube (n=2); (20,48) Gastroscopy/ endoscopy/ 
enteroscopy (n=64); (28,35,40,50,62,65,73) rectal enema (n=156) (11–13,24,41,57,72,77,79) which was 
repeated again 3 days later in once case; (11) Colonoscopy (n=530). (1,3,14,16–19,22,25–27,29,32,38,43–
48,50,51,54,56,58,60,62,63,66–69,80–82) Simultaneous jejunal (via enteroscopy) and colonoscopic 
infusion was administered in 40 cases. (53,55,71) Two case series comprising six (59) and seven 
cases (52) described patients receiving faecal enema at home, self-administered or by a  family 
member. One patient had both enteroscopic and colonoscopic FMT.(62) FMT instilled through 
a previously placed gastric tube was described in 5 cases. (31,65) One patient refusing invasive 
procedures had FMT administered trans-rectally over 10 minutes having had the solution 
drawn and instilled into 20 5ml syringes. (33) Another underwent FMT twice in 10 days firstly 
via an ‘intestinal tube’ and then by colonoscopy. (39) Only in one paper was FMT 
administered intentionally to manage both for CDI and concurrent inflammatory bowel 
disease, Crohn’s (n=7) and Ulcerative Colitis (UC) (n=6). (84) 
In 132 of 1190 CDI cases, one or more FMT additional procedures were administered. 
(1,8,27,32,42,48,50,54,56,59–61,63,64,66–68,72,75–78,82) One patient was finally successfully treated with a 
bacterial suspension enema following failed enema of faeces. (41) 
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Adverse events as a result of FMT given for C.difficile infection 
 
Procedural Complications 
In only four cases was an adverse event directly attributable to the FMT procedure itself. 
These comprised: ‘microperforation’, described as following biopsy of an area of ‘presumed 
ischaemic small bowel injury’ during the FMT procedure. This resolved with conservative 
management. (63)  Caecal perforation at FMT necessitating colectomy.  (64)  ‘Minor mucosal 
tear’ during colonoscopy to deliver FMT. (51) One FMT procedure was abandoned after the 
discovery of chronic graft versus host disease of the terminal ileum in a stem cell transplant 
recipient patient that had been persistently PCR positive for the C.difficile toxin gene. (78) 
 
Infective Complications  
Norovirus transmission possibly associated with FMT has been reported in 2 cases (46) both 
cases testing positive for norovirus by PCR. One presented day 2 post FMT with diarrhoea 
but the donor was asymptomatic and tested negative and the second case presented with 
vomiting and diarrhoea 12 days post FMT, again with an asymptomatic donor who was not 
tested. 
 
A patient diagnosed with influenza B 3 days post FMT was not thought to be infected 
through the FMT as the donor remained asymptomatic throughout the 12 week follow up 
period. (76) Gram negative bacteraemia occurred in four cases after FMT. (28,31,38,85) two of 
whom died as a result of the procedure. (31,85)  Escherichia coli bacteraemia occurred 24 hours 
after colonoscopic FMT in a 61 year old man with concomitant Crohn’s disease and 
diverticulitis who had had 6 prior Escherichia coli bacteraemias in the preceding 3 and half 
years – leading the authors to postulate that altered intestinal permeability was the cause. The 
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case responded to antibiotics. (38)  Another case involving Serratia spp bacteraemia occurred 
12 days following jejunal- placed FMT – the patient dying more than 30 days after the 
procedure from recurrent ventilator-associated  pneumonia.  A CT scan prior to death showed 
no evidence of colitis, and  stool cultures remained negative for culture and toxin 14, 20 and 
30 days post-transplant. (28) The remaining two cases were bacteraemia are described in the 
section on deaths associated with FMT. 
 
Inflammatory Complications  
Fever of unknown cause  
Fever in the absence of an identified infectious agent was reported in 11 cases, (1,69,71,73,76) 
with only one specifying the temperature reading, at 38.8 degrees 2 days post FMT. This 
resolved spontaneously. (1) Fever was described by authors as ‘mild and transient’ in 2 cases, 
(69) ‘low grade’ in 5 (resolving spontaneously within 12-24 hours). (71) One case reported 
spontaneous resolution of fever with negative blood cultures. (73) Fever, diarrhoea, 
encephalopathy and pancytopenia 4 days post FMT were described in a patient with cirrhosis 
and non-Hodgkin’s lymphoma (the management and outcome were not discussed),  (76) fever 
was also recorded post FMT in a solid organ transplant recipient. (76) 
 
Exacerbation of Inflammatory Bowel disease  
In patients with concomitant inflammatory bowel disease and CDI (where FMT was 
administered primarily for CDI) clinical deterioration occurred in six cases (25,76) Four out of 
five cases in one series  (76)  were hospitalised with a flare of IBD within the 12 week follow 
up period.  Colectomy within 1 month of FMT was necessary in one case due to worsening 
ulcerative colitis, whilst another two underwent colectomy 105 and 293 days after FMT 
respectively. A patient with UC described as ‘quiescent’ for 20 years presented 9 days post 
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colonoscopic FMT with abdominal cramping and loose bloody stools with mucus. Repeat 
colonoscopy showed new features consistent with UC when compared to the previous 
appearance  on colonoscopy to deliver FMT and biopsy confirmed inflammatory colitis. (25) 
 
In the only paper describing colonoscopic FMT for concomitant IBD (Crohns n=7 and UC 
n=6) and CDI omitted to mention whether any adverse events occurred, but did report that of 
the 11 clearing their CDI infection, 46% required escalation of their IBD management. (84) 
 
 
Gastrointestinal Complications 
Gastrointestinal side effects were the most commonly reported although terms were 
inconsistent and imprecise. Symptoms included flatulence (n=25); (56,77,80) diarrhoea (n=18); 
(51,58,75,76,80) irregular bowel movements (n=14); (56) post infectious inflammatory bowel 
syndrome (n=13); (52,68,74) abdominal distension/bloating (n=12); (1,71,76,80) abdominal 
pain/tenderness (n=11); (75,76,78,80) constipation (n=10); (14,77) cramping (n=9); (73,80) nausea 
(n=7) (the route of administration was not recorded); (75,76) blood in stools (n=2) (both cases 
had concomitant inflammatory bowel disease); (80) microscopic colitis (n=2). (68) Other 
miscellaneous comments included ‘intermittent obstipation’; (24) mucoid stools; (80) ‘visceral 
hypersensitivity’ (68) and ‘a few patients developed temporary constipation’. (72) 
 
The outcomes of these symptoms were often not recorded but largely the terminology used to 
describe them gave the impression they were not deemed to be significant adverse events 
with descriptions as mild, (86) short lived, (80)  transient (73,77) and self limiting, (8,71) though  in 
one paper over the counter fibre preparations had been used to manage side effects. (58) There 
were very few descriptions of longer term symptomatic cases, these included 5 cases of post-
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infectious IBS remained symptomatic at the end of the study follow up period at 16-35 
months (74) and constipation that persisted ‘for months’. (14) 
 
 Deaths Potentially Attributable to FMT  
Three deaths have been described in patients undergoing FMT. (31,76,85) One patient, after an 
uncomplicated FMT delivered via a pre-existing gastric tube, developed septic shock 3 days 
later with decompensated toxic megacolon, and blood cultures yielded Pseudomonas 
aeruginosa, Escherichia coli, Lactobacillus casei. The patient died of septic shock 4 days 
after colonic resection. The authors conclusion was that the link to FMT was unclear. (31)  A 
second patient died of respiratory failure one day after aspirating during sedation to deliver a 
colonoscopic FMT. (76) We have also reported a case of regurgitation of faeculent material 
during endoscopic FMT under general anaesthetic followed by aspiration pneumonia and 
septic shock. The patient died 48 days later. (85) 
 
Other deaths in the follow up period 
Other deaths which occurred in patients that had undergone FMT for CDI were reported in 41 
cases (1,3,49,50,54,60,63,64,68,76) summarised in Table III. Of these, seven were attributable to 
C.difficile infection. (50,60,68) In one case series 3 deaths occurred within 1.5 to 3 months of 
FMT all having severe diarrhoea pre-transplantation associated with the hypervirulent 
ribotype 027. (60) Another described 3 patients who failed to respond to FMT and died within 
3 weeks to 2 months of the procedure, two of whom were described as ‘seriously weakened 
after long lasting diarrhoeal disease’ and another died of complications related to subtotal 
colectomy after developing fulminant colitis. (50) Another death was attributed to complicated 
CDI without further detail. (68) 
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Other reported events 
Events that do not fall into the above categories are tabulated in table IV. These include 
reports from publications listing any untoward event without necessarily ascribing them 
directly to the FMT procedure. Table V shows crude rates for the commonest reported 
symptoms and adverse events following FMT. As there is no standard for classifying and 
reporting these adverse events following FMT, we expect that there is likely to be significant 
underattainment.  
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FMT to treat Inflammatory Bowel Disease  
Excluding the RCT for UC previously discussed, (9) 226 of the 1555 ascertained underwent 
FMT primarily for inflammatory bowel disease.  Amongst these were 159 procedures for 
ulcerative colitis (83,87–100) and 67 for Crohn’s. (92,100–107) In addition eight patients underwent 
FMT for pouchitis following restorative proctocolectomy for ulcerative colitis, (108) three for 
mixed UC/Crohns (109) or IBD unspecified. (110) Concomitant CDI was present in 6 patients. 
(90,93) Publications ranged from four single case reports (99,106,107,110) to series ranging from 3 
(97,109) to 62 patients. (89) 
 
Modes of delivery 
Methods of administration of FMT in these cohorts were highly variable, including 
nasogastric tube (n=18); (104,108) naso-duodenal tube (n=10); (95) endoscopy (n=31) (102,106) and 
colonoscopy (n=31), (90,91,96,100,103,110) the latter repeated at 4 and 12 weeks for one patient.  
(110) Rectal enema was described using a variety of regimens in 17 cases. (94,98,109) Training in 
self-administration of FMT allowed one patient to complete 69 procedures in total, initially 
daily then weekly. (109) A plethora of other  methods of administration combine different 
routes in largely inconsistent regimens,  including 25 cases of initial colonoscopic FMT 
(90,93,97,105,109) and one case of initial naso-jejunal infusion (93) followed by a variable number 
of rectal enemas. The remaining 21 were described as ‘self-administered faecal enemas in a 
tapered then maintenance schedule’. (90,93) Another approach involved daily administration of 
combined nasojejunal infusion and rectal enemas (n=5). (88) In 16 patients using home- based 
faecal transplant, the authors did not specify their methods further. (87) Four patients had ileo-
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colonoscopy and biopsies followed directly instillation of FMT via NJ tube which was 
repeated twice the following day. (101) 
 
Adverse events of FMT given for Inflammatory Bowel Disease 
Procedural 
Inability to tolerate retention of a faecal enema with immediate leakage on 3 consecutive days  
and secondly low back pain (94) were each reported, both in children.  This uncommon side 
effect probably resulted from the complex positioning for the procedure adopted. Patients 
were rotated 180 degrees left lateral to right lateral over a 10 minute period, in the left lateral 
decubitus position with elevated hips, then received four retention enemas in 60ml aliquots 
every 15 minutes. 
 
Fever and raised inflammatory markers  
As with CDI, fever was the most frequently encountered inflammatory adverse events in  14 
cases, (88,91,94,100–102) this was quantified in two  as greater than 38 degrees Centigrade with 
negative blood cultures; (88) up to 39 degrees in one case, self limiting after 3 days which the 
authors concluded this was non-significant and interpreted as an ‘immunological reaction to 
the applied bacteria to the inflamed colon’; (91) ‘transient’ in three cases; (101) ‘mild’ in one 
case; (100) one episode of fever was accompanied by ‘chills’  responding to acetaminophen 
and antihistamines and did not recur with further FMTs. (94) In a further two cases of fever 
these were considered doubtful adverse events as the patients had fever after colonoscopy 
under general anaesthesia before FMT. (102) 
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Deterioration in IBD was also described in 6 cases;  (88,90,94,96)  of which one was described as  
‘disabling haematochezia’ three weeks after FMT; (94) other reports include increased CRP 
(n=6). (88,91) Only one of which was quantified at 31.5 mg/L, this patient also had a raised 
interleukin-6. (91) Itchiness (88) and erythema (88) were described in individual cases but these 
were not described further. A case of ‘hives’ occurred in a patient with history of medication 
allergies during the 7 day follow up period following colonoscopic FMT of anonymous donor 
faeces. (100) 
 
Gastrointestinal 
Again gastrointestinal adverse effects predominated (Table VII) with; diarrhoea (n=28); 
(88,91,94,100,102,104) abdominal distension/bloating (n=24); (92–94,100,104) abdominal 
pain/cramping/tenderness (n=20); (94,100,101,104) flatulence (n=10); (88,94) vomiting (n=3); (88,104) 
Constipation (n=5) (100) bloody stool (n=4) (94,98) (one following withdrawal of prednisolone) 
(98) and ‘mild-moderate diarrhoea observed and self-limiting’ without specifying the number 
affected described. (95) 
 
Other reported events 
Other reported adverse events of uncertain/ if any relation to faecal transplant are shown in table VI. 
  
 
 FMT to treat Irritable Bowel Syndrome (IBS) 
FMT was used in attempt to treat IBS in 18 cases. (105,111) The first study (111) described a total 
of 13 patients,   11 undergoing one FMT, one having two and one having three procedures. 
The time course, method and necessity for further FMTs were not specified. The second case 
series (105) involved colonoscopic infusion of faeces followed by various regimes comprising 
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4 enemas (n=2), 9 enemas, 4 nasojejunal infusions then 5 enemas and 5 combined 
nasojejunal infusions and enemas. There were no adverse events described in either study. 
 
FMT to treat Constipation   
FMT as a treatment for constipation has been described in 7 patients. (105,112) The route of 
administration was described in 4 cases and included two cases that had their FMT as a 
colonoscopic procedure followed by 9 enemas. One patient had 15 enemas as daily infusions, 
and another had a regimen that consisted of colonoscopic FMT followed by 5 combined 
nasojejunal infusions and enemas followed by a further 5 enemas. (105) In the remaining 3 
cases it was noted only that two had 5 FMTs with the method not recorded and a third had 10 
days of FMT infusions. (112) There were no reported adverse events in any of these studies.   
 
FMT used in other conditions  
Several cases of Pseudomembranous colitis unattributed to C.difficile infection have been 
treated with FMT (n = 21). (6,113,114) However it is noteworthy that these papers were 
published either before (6,113) or shortly after (114) the association of C.difficile and 
pseudomembranous colitis being first reported in 1978(115). Various methods of 
administration were described; ‘a long enteral tube’ in one case, (114) 15 patients had retention 
enemas given twice daily ‘in almost all circumstances’. (114) The remaining five were given as 
retention enemas once, (113,114) twice (n=2) (6) and three times (n=1). (6) Despite no directly 
attributable adverse events being reported, overall three patients died (duration of follow up 
was not recorded). (114) Of these, one had no pseudomembrane noted at autopsy, the second 
had no endoscopic evidence of the disease and died of pneumonia, whilst the third failed to 
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respond to faecal enema clinically and was found to have pseudomembranes involving most 
of the small bowel at autopsy. Another case series of 9 patients treated with FMT for 
antibiotic associated diarrhoea (not specifying whether C.difficile related ) (116) suffered  no 
reported adverse events on 18 month follow- up. 
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Discussion 
We have comprehensively reviewed the available literature on FMT published before 
November 2014 to determine what adverse events may be encountered. The literature 
surrounding FMT is largely of poor quality in that it is dominated by anecdotal case reports 
and small series without comparators or controls. There are only three small randomised 
controlled trials (8–10) reporting only 52 of the 1555 patients covered by the literature.  
 
We found that there was wide variation in all areas of methodology, such as in patient and 
donor selection; preparation and administration of the transplant; number of procedures per 
patient; follow up and reporting of outcome data. In many of the reports no information on 
adverse events was included. Without any standardisation or structure it is not possible to 
provide a robust assessment of the range and incidence of significant adverse events. In 
addition the follow up period was highly variable from about 1 week (100) to 15 years. (112) 
 
FMT has been applied beyond the treatment of CDI where its use is well established, to 
ulcerative colitis (10,83,84,87–99) Crohn’s disease (92,100–107) and mixed IBD. (109) Pioneering 
application in patients with constipation, (105,112) metabolic syndrome (9) and IBS (105,111) has 
been reported, raising questions as to the exact pathophysiology of these conditions. FMT has 
also been given to paediatric patients suffering CDI (17,18,21,76,80) and ulcerative colitis. (94,97,104) 
Non-IBD immune-compromised patients receiving therapy range from those chronic medical 
conditions to solid organ  (n=23) (30,35,48) and haematology transplant patients(20) have also 
been described. Use of FMT has been reported in  four cases with HIV, (39,76) and seven 
patients with concomitant use of  ‘antineoplastic agents’. (75)  In addition to these patients 
some of whom were severely immunocompromised individuals, 
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FMT as a salvage therapy has also been employed in intensive care unit patients  for 
unresponsive fulminant CDI. (13,28,37) Comparison between patients with such a heterogeneous 
range of conditions risks confounding true adverse effects with conditions that are part of the 
natural progression of disease. 
 
The literature esteems the use of FMT in CDI(2) where the FMT  replenishes the defective 
diverse range of non-pathogenic colonic flora that act to prevent proliferation of Clostridium 
difficile.(3) Because of the extent of case reports in CDI it is possible to summarize the 
emerging themes of adverse events. The procedure is generally safe, and side effects 
experienced mild and self-limiting (Table V). Nevertheless there are limited reports of 
serious adverse events, bacteraemia, inflammatory bowel disease flares, and death. Without 
proper comparators it is not possible to be certain that these are significant risks in a 
condition which itself has a high morbidity and mortality. (117) 
 
In IBD, where the interplay of microbiota, host resistance and inflammatory mediators  is 
more poorly understood, (98,102) the role and outcomes of FMT is less well defined. Use in all 
forms IBD is the second most commonly reported indication for FMT, though the numbers of 
patients are small, 278 (17.8%). Some authors reporting successful outcomes 
(89,98,99,102,103,106,107,109,110) while others are more guarded, reporting more variable results or no 
discernible  improvement.(10,91,93,101,104) In a relapsing and remitting condition the significance 
of adverse events such as flares and deteriorations are difficult to delineate the natural history 
of the disease. 
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The long term effects and outcomes of FMT are yet to be established. This may be of concern 
as the gut microbiome becomes increasingly implicated in disease states. (35) The majority of 
patients with CDI are elderly often with other serious conditions, but many other recipients of 
FMT are likely to be much younger. For them the long term consequences of manipulation of 
the gut microbiome must be understood. For example are anecdotal reports of changes that 
have occurred after FMT. These include improvements in comorbid conditions; reversal of 
immune thrombocytopenic purpura (99) and neurological symptom reversal in three patients 
with multiple sclerosis. (112) In two patients, the resistant coliforms present prior to FMT were 
supplanted by ciprofloxacin sensitive coliforms post FMT. (108) FMT for refractory CDI 
resulted in an apparent improvement in the associated urinary organisms exhibiting 
‘significantly decreased drug resistance”(48) a principle further supported by two case  reports 
using FMT to decolonise patients with multi-drug resistant carbapenemase producing strains 
of Klebsiella pneumoniae. (118,119) Others have noted improvement in pre-existing allergic 
sinusitis (54) arthritis (54) In one series treating Crohns with FMT 8/11 of the patients noted 
relief of concomitant ‘skin lesions’(102) a phenomenon also seen in another group using FMT 
to treat UC where three cases had improvement in ‘skin problems’ as well as reduced insulin 
requirements in a diabetic patient (95) Since undertaking our recent search there has also been 
a case report published linking FMT to the development of obesity.(120) 
 
On the whole adverse events largely appear to be gastrointestinal in nature, and some have 
very nebulous association with the procedure. Most are mild and self-limiting, but there were 
deaths directly attributable to the procedure. We noted relatively higher rates of adverse 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
 
events in the IBD groups than the CDI group which may indicate the underlying condition 
itself predisposing to the risk of adverse events.  
 
Limitations 
We have presented those adverse events reported to date. Important limitations are 
1. the search was limited to reports in the English language 
2. every effort has been made to remove the duplicate reports but it is possible that some 
patients have been included in more than one publication 
3. there is a global lack of standardisation around the practice of FMT 
4. there is an absence of structured follow up and reporting of outcome data including 
adverse events 
5. given the dominance of case reports and case series in the literature there is likely to 
be reporting bias that may affect the prevalence of adverse events 
6. there is a lack of high quality randomised trials on FMT, especially for applications 
other than CDI 
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Conclusion 
On reviewing the adverse events reported in association with FMT, we find the vast majority 
are generally mild, self-limiting and gastrointestinal in nature. In some a credible association 
is not established, due to the lack of controlled data. There have however been a few reports 
of serious adverse events. From the limited data we have collected, it may appear that rates of 
adverse events appear to be higher in IBD than CDI. However there is a need for 
standardised, randomised controlled trials both to qualify and quantify the risks of faecal 
transplant – which may of course change with time as the function of the microbiome is 
further defined.  
 
Potential recipients of FMT can only give informed consent if they understand the potential 
for adverse outcomes. Whereas we feel this may be possible for CDI, the quality of data 
available for other indications is so poor that the information required is not available. 
 
It is important to establish standardised and where possible evidence based procedures for 
FMT. These should cover both the procedural aspects of FMT, but recording of outcomes in 
a standardised and comprehensive format. In view of the potential for long term effects 
following a procedure such as FMT there is a need to establish national registries.  
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Table I 
Indication for FMT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Unspecified whether related to CDI  
**Not as a result of CDI but these include publications prior to or shortly after the association    
    between C.difficile and pseudomembranous colitis being made 
Indication for FMT 
Number of 
patients 
(n=1555) 
C.difficile infection 1190 
Ulcerative colitis 186 
Crohns disease 67 
Antibiotic associated diarrhoea* 32 
Pseudomembranous colitis** 21 
IBS 18 
Concurrent IBD/CDI 13 
Metabolic syndrome 9 
UC pouchitis  8 
Constipation 7 
IBD mixed or unspecified 4 
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Table II  
Adverse events reported from the randomised controlled trial for FMT in CDI 
 
Adverse events from the RCT for FMT in CDI (8) 
Vancomycin & bowel lavage & 
FMT (n=16)* 
Vancomycin & bowel lavage 
(n=13) 
Vancomycin only 
(n=13) 
Diarrhoea (n=15) Constipation (n=2) Death (n=1) *** 
Abdominal Cramps (n=5) Diarrhoea** (n=1) Diarrhoea (n=1) 
Belching (n=3) ‘Excessive gas’ (n=1) Constipation (n=1) 
Constipation (n=3) Urinary tract infection (n=1) Pain (RA) (n=1) 
Abdominal pain (n=2)   
Nausea (n=1)   
Fever during dialysis (n=1)   
Urinary tract infection (n=1)   
Dizziness & diarrhoea (n=1)   
Choledocholithiasis (n=1)   
 
 
* Diarrhoea, abdominal pain/cramps and belching all resolved within 3 hours of FMT. 
Events during follow up – fever on dialysis was treated with antibiotics, blood cultures                                      
were negative, the UTI case had a history of recurrent UTIs. The case with dizziness and 
diarrhoea had a history of autonomic dysfunction. 
 
** Subsequently diagnosed with Crohns disease.  
 
*** Death was deemed unrelated to study drug. 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
35 
 
 
Table III  
Deaths reported following FMT that were not attributed to FMT by the authors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cause of Death (Time after FMT) 
 
Reference 
Pulmonary disease (n=6) (1,3,49,54,64,76) 
CDI related (n=7)  (50,60,68) 
Malignancy (n=5) (1,3,54,60,63) 
Co-morbid conditions 
unspecified/unrelated (n=17) 
(50,60,68,76) 
Superior mesenteric vein thrombosis (5 months) (3) 
Sepsis in a Crohn’s patient (5 months)  (54) 
Cerebrovascular event  (54) 
Myocardial infarction (54) 
Unknown (54) 
PD peritonitis (day 3) (49) 
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Table IV  
Other reported events following FMT for CDI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse event (Time after FMT) 
 
Reference 
Proteus spp UTI (day 33) (45) 
Herpes zoster (8 weeks)  (60) 
Pneumococcal meningitis  (60) 
Pertussis  (76) 
Line infection (n=2)  (26,39) 
Fall, hip fracture (76) 
Upper GI Haemorrhage (42) 
Hip pain  (76) 
Cerebrovascular accident (day 21) (76) 
Anxiety (n=6) (75) 
Oesophageal carcinoma  (1) 
Fournier’s gangrene (1) 
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Table V 
Overall rates of the commonest adverse events with the denominator as the total number of 
cases receiving FMT for CDI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* This includes a case report (85) we have published since the search – therefore this one case 
is not represented in the overall denominator figure (the percentage rate however remains 
unchanged by this addition) 
Effect 
Number of 
patients 
Overall % 
(n=1190) 
Abdo distension/bloating/cramping 28 2.35% 
Flatulence 25 2.1% 
Diarrhoea 23 1.93% 
‘irregularity of bowel movements’ 14 1.18% 
IBS Symptoms 13 1.09% 
Constipation 13 1.09% 
Abdominal pain/tenderness 11 0.92% 
Fever 11 0.92% 
Nausea 7 0.59% 
IBD flare/deterioration 5 0.42% 
Gram Negative Bacteraemia  4 0.34% 
Perforation/tear 3 0.25% 
Belching 3 0.25% 
Attributable death* 3 0.25% 
Blood in stools 2 0.17% 
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Table VI 
Other reported events following FMT for IBD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Described by the authors as baseline symptoms from concurrent medication use and not  
attributed to FMT. 
 
 
 
 
 
Adverse event (Time after FMT) 
 
Reference 
Hip paraesthesia  (88) 
Collapse  (88) 
Blisters on tongue (88) 
Fatigue (n=3) (94) 
Cervical lymphadenopathy (post URTI)  (94) 
Headache, nausea and vomiting* (94) 
Self-limiting headache  (97) 
‘Severe cold’ (3 weeks)  (106) 
‘common cold’ (n=3)  (88) 
‘mild stuffy nose/sore throat/drippy nose’ (n=4)  (104) 
Headache  (100) 
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Table VII 
Overall rates of the commonest adverse events using the denominator as the total number of 
cases receiving FMT for IBD. 
 
 
 
 
 
 
 
 
 
 
 
Effect 
Number of 
patients 
Overall % 
(n=265) 
Diarrhoea 28 10.57% 
Abdominal distension/bloating 24 9.06% 
Abdominal pain/cramping/tenderness 20 7.55% 
Fever  14 5.28% 
Flatulence 10 3.77% 
Deterioration of IBD  6 2.26% 
Raised CRP  6 2.26% 
Constipation 5 1.88% 
Blood in stools 4 1.50% 
Vomiting  3  1.32% 
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Figure 1 
 
 
 
Publications of FMT use arranged by year of publication from first description in 1958 to 
2014, demonstrating the surge of FMT use in the preceding 5 years.  
 
 
 
 
 
 
 
 
 
Figure
Figure 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overview of search strategy 
F(a)ecal transplant, f(a)ecal transplantation,  f(a)eces transplant,  f(a)eces transplantation, f(a)ecal 
bacteriotherapy, f(a)ecal microbiota transplant, f(a)ecal microbiota  transplantation, f(a)ecal microbiota 
transplanted, F(a)ecal bacteria therapy, Stool infusion, stool infused, f(a)eces infused, f(a)eces infusion, f(a)ecal 
infusion, f(a)ecal infused, f(a)eces enema, , f(a)ecal enema, f(a)eces within 2 words of infusion/infused. 
Limited To humans, English language 
Medline  Embase 
1664 abstracts reviewed   3915 abstracts reviewed   
3551 discarded  
383 results with FMT in abstract or keywords 
Review of 
bibliographies 
(n=3)  
1 unable to access 
(Single case report)  
29 excluded 
 
o Same  cohorts (n=18) 
o Self-administered (n=1)  
o Review/did not 
administer FMT first-
hand/ other (n=9) 
o Synthetic stool (n=1)  109 Unique publications using FMT 
Duplicates removed 
171 selected         364 selected 
139 papers selected 
Administering FMT  
1493 discarded  
  
 
 
